Uncategorized

OhioHealth has agreed to void problematic contracts with insurers and not seek such terms moving forward, the Justice Department said. The Ohio nonprofit continues to deny all wrongdoing.

Aaron Lewis, who has served as CFO since 2024, takes on the role as the health system looks to expand its footprint and add new services.

The No Surprises Act “might not have the effects that CBO anticipated,” the agency wrote in petitioning for more research into the 2020 law’s effect on healthcare prices and other trends. It’s a welcome development for payers.

Honestamente, el panorama empresarial actual está cambiando a una velocidad que a veces asusta un poco. No se trata de una evolución lenta ni de cambios superficiales que se puedan ignorar. La llegada de la inteligencia artificial ha modificado las reglas del juego de una manera tan pr …

Deal volumes and values are tracking above the first half of 2025, driven by Boston Scientific’s Penumbra buyout and Danaher’s Masimo acquisition.

The shortage follows Hologic removing certain breast biopsy needles from the market in January.

After a regulatory odyssey that delayed a filing for what would be the first genetic medicine for Huntington’s disease, the FDA has agreed that three-year data from uniQure’s Phase 1/2 trial are sufficient to support an accelerated biologics license application.

The average number of issuers fell from a record high of 9.6 per state in 2025 to just nine this year, according to the health policy research group.

Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs.

MMI built a robot to help surgeons perform microsurgical procedures with more control than is possible with the human hand alone.